Bristol Myers and 2seventy win label expansion for Abecma in earlier multiple myeloma
Bristol Myers Squibb and 2seventy bio’s CAR-T therapy Abecma will now be available to earlier-stage multiple myeloma patients.
The drug, also known as ide-cel, won FDA approval on Thursday in the third-line setting. BMS has touted the indication as an important shift from the fifth-line setting, as many multiple myeloma patients eventually relapse or develop resistance to other available treatments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
